Oxford Biomedica PLC Block listing application (5773R)
12 December 2016 - 9:52PM
UK Regulatory
TIDMOXB
RNS Number : 5773R
Oxford Biomedica PLC
12 December 2016
Oxford BioMedica
Block listing Application
Oxford, UK - 12 December 2016: Oxford BioMedica plc ("OXB" or
"the Group") (LSE: OXB), a leading gene and cell therapy group,
announces that application has been made to the UK Listing
Authority and the London Stock Exchange for (i) admission to the
Premium segment of the Official List and (ii) to trading on the
London Stock Exchange for a block listing of 10 million ordinary
shares of 1 pence each (the "Ordinary Shares").
The Ordinary Shares are being reserved under a block listing and
will be issued from time to time pursuant to the Oxford BioMedica
2015 Deferred Bonus Plan.
It is expected that admission of the Ordinary Shares will become
effective on 15 December 2016. The Ordinary Shares will rank pari
passu in all respects with the Group's existing ordinary shares in
issue.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Notes to editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and
ex-vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
250 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSBLLFFQLFEFBF
(END) Dow Jones Newswires
December 12, 2016 05:52 ET (10:52 GMT)